Primary lung cancer is extremely rare in children. It often presents with metastatic disease and carries a poor prognosis. Adenocarcinoma is the most common type of bronchogenic carcinoma in children and adults. Our aim was to systematically review the presenting features, approach to diagnosis and management, as well as the outcomes of primary pediatric adenocarcinoma of the lung. This systematic review was prospectively registered with PROS-PERO. The following databases were searched: Medline, Embase, Web of Science, and Scopus for English language cases of primary pediatric adenocarcinoma of the lung. Forty-eight studies were included, comprising 62 patients with adenocarcinoma and 21 cases of adenocarcinoma in situ. Presenting features were nonspecific, with cough and dyspnea the main symptoms at diagnosis. The majority of patients with adenocarcinoma had metastatic disease at diagnosis. Surgery was the most common form of management. More than half the patients with adenocarcinoma had died at final follow-up, whereas 5 of 21 with adenocarcinoma in situ died. Medical management did not improve outcomes, except for two ALK receptor tyrosine kinase (ALK)-rearranged adenocarcinomas that responded to ALK inhibitor therapy alone. Primary pediatric adenocarcinoma of the lung is a rare entity which often presents with metastatic disease and portends a poor prognosis. Surgery is associated with disease-free status, although new agents such as ALK-inhibitors are able to prolong life without surgical management.
Introduction
World-wide primary lung cancer is the one of the most common adult cancers and is the leading cause of cancer-related death.
1,2 However, the incidence of primary lung cancer in children is rare, estimated to be 1 in 2 million, or 0.2% of all childhood malignancies. 3 The ratio of lung malignancies in childhood is 1 primary lung malignancy (of any histopathologic type) to 5 metastatic (commonly from sarcoma, germ cell tumors, Wilms' tumor, and neuroblastoma) and 60 inflammatory or congenital premalignant tumors (such as pulmonary blastoma). 4, 5 Adenocarcinoma is the most common type of lung cancer in adults, and in younger patients (26 to 40 years of age) it is found in higher proportions than other forms, such as squamous cell carcinoma or small cell lung cancer, the latter two subtypes most closely linked with cigarette smoking. 2, [6] [7] [8] One review suggests adenocarcinoma is also the most prevalent pediatric bronchogenic carcinoma, although its true incidence has not been established. 9, 10 Comparing lung cancer presentation in adults versus the pediatric population, there are several similarities. There are generally delays between presentation and ultimate diagnosis of pediatric lung cancer. Multiple studies cite nonspecific presenting symptoms such as persistent cough, treated with several courses of antibiotics before the diagnosis, and only 6% of pediatric lung cancers appear to be truly asymptomatic at presentation. 2, 4, 9, 11, 12 Other common presentations include chest pain, wheeze, hemoptysis, and occasionally symptoms due to metastatic disease. 10 Persistent radiological abnormalities or incidental findings on screening imaging may also lead to the diagnosis. 5 The nonspecific nature of clinical presentation and rarity of the condition result in many cases of lung cancer in younger people having metastatic disease at diagnosis, which mirrors adult lung cancer where diagnosis can be delayed due to nonspecific presenting symptoms. 3, 11, 13 Stage IV disease is present in up to half of the cases at diagnosis. 7, 12 As such, it has a poor prognosis, with one case series having a median survival of 14 months and 5-year survival rate of 26% for pediatric adenocarcinoma of the lung. 3 It is thought that the biology of non-smoking-related primary lung cancer is also similar, regardless of age. 14 No oncodrivers or gene mutations that are unique to pediatric lung cancers have been identified, although the prevalence of some types of mutations differs with age. Other predisposing factors include congenital cystic airway mutations. 13, 15 With respect to adenocarcinoma, the histopathologic criteria for subgroup classification is the same for adult and pediatric cases. Molecular mutation testing is conducted for confirmed adenocarcinoma, as per adult lung cancer guidelines, looking for somatic mutations such as EGFR, KRAS, BRAF, ALK receptor tyrosine kinase (ALK), or ROS-1.
16 ALK mutations are seen in a higher proportion of younger patients with lung carcinoma (26 to 40 years old), with approximately 11% of adenocarcinoma being ALK-positive compared with 2% to 7% of adenocarcinomas in adults. 1, 17, 18 EGFR and KRAS mutations are found in 20% and 25% of younger adult lung adenocarcinoma cases, respectively. 18 There are no data specific to the pediatric population regarding the incidence of ALK, EGFR, or KRAS mutations in NSCLC. ALK, EGFR, and KRAS are particularly relevant due to recent progress made in treating NSCLC with targeted agents, such as crizotinib or alectinib for ALK rearranged cancers or erlotinib and gefitinib for EGFR mutations. 16, 19 There is limited pediatric-specific evidence to define optimal management of lung adenocarcinoma in this population, so treatment recommendations are extrapolated from adult protocols. 19 Generally, management is focused upon surgery, chemotherapy, radiotherapy, or some combination of these. 20 Studies in younger adult patients report higher proportions of surgical management compared to the elderly. 3, 7 Surgical management is thought to be a significant positive prognostic factor for children with lung cancer. 3 In adult NSCLC, surgical management of the thoracic primary is recommended for early-stage (I and II) and resectable-stage III disease, and in good performance status patients (Eastern Cooperative Oncology Group performance status 0-1) presenting with stage IV limited metastatic disease (usually solitary cerebral metastasis) and otherwise imaging-confirmed localized thoracic disease.
20
Our primary aim was to systematically review the literature to determine the demographic and presenting features of children and adolescents with adenocarcinoma of the lung. Further, we will review treatment modalities and their outcomes to provide an evidencebased summary for recommendations for care of patients in the future.
Materials and Methods
This systematic review was prospectively registered with PROSPERO (CRD42018093670). The Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement was followed in the writing of this review. 21 
Search Strategy
A systematic search was conducted to identify publications regarding adenocarcinoma of the lung in children and adolescents 18 years of age and younger. The following databases were searched: Medline, Embase, Web of Science, and Scopus from dates of inception to April 2018. A further search was performed for "grey" literature using Google Scholar. The search strategies are listed in the supplementary material. The reference lists of relevant manuscripts were hand-searched for further records.
Inclusion Criteria
We included English-language studies of primary adenocarcinoma of the lung in children aged 18 years or younger that described diagnosis, treatment modalities, and outcomes. Where studies included people older than 18 years, subgroup reporting of those younger than 18 was required for inclusion. Bronchoalveolar carcinoma (BAC), now called adenocarcinoma in situ (AIS) (provided the tumor lacks stromal, vascular, or pleural invasion) was included, although it was analyzed separately as its pathology, treatment, and prognosis varies from adenocarcinoma. 22 Exclusion criteria included cases involving synchronous malignancies, lung adenocarcinoma diagnosed after another malignancy, and conference abstracts.
Data Collection and Analysis
Study Selection. Once irrelevant studies and duplicates were removed, one reviewer (B.B.) scanned the title, abstract, and keywords of the remaining articles. Where a reference met inclusion criteria, the full text was retrieved for further analysis by two reviewers (B.B. and A.A.) and was either included or excluded based on the above criteria. Discrepancies were resolved by consensus. Relevant data were extracted from the included studies using a template designed by the authors.
Data Extraction and Synthesis. The following data were extracted: publication year, study type, age and sex of patient, presenting history and examination, imaging modalities used, stage at diagnosis (using the Eighth Edition Lung Cancer Stage Classification), histopathologic diagnosis and subtype (where stated and based on contemporary classification) as well as relevant immunohistochemistry and cytogenetics, treatment modalities (surgery, radiotherapy, or chemotherapy) and their complications, follow-up duration, and status at final follow-up (disease-free, alive with disease, or death). 23 Given the nature of the retrieved manuscripts, metaanalysis was not performed and the results are presented as descriptive data.
Quality Analysis. As 32 of 34 included studies were case reports, a quality assessment tool was created by the authors based upon the CARE guidelines. 24 The quality analysis of included case reports is provided in supplementary material. The two case series described in Table 1 do not provide additional description of case presentation or treatments, other than in broad terms. Most case reports provide adequate historic and examination findings and all provided histopathology results, with allowance made for year of publication for the quality of histopathology results (such as discovery of new staining techniques). In all but 5 cases, treatment was described. Three of these were autopsy studies and two were cases from a historic chart review which did not clarify type of chemotherapy used. 4 All studies except four AIS cases provided follow-up outcome data.
Results

Search Results
The search results and study selection are displayed in Figure 1 . The initial database searches identified 3275 titles, of which 152 unique titles were relevant. A further five references were added after search of the grey literature and reference list searching yielded 11 more references. One hundred five references and their abstracts were screened, with 92 full text studies reviewed. Forty-eight studies remained eligible after reviewing the full text articles.
Included Studies
Adenocarcinoma. Thirty-four studies were included, comprising two case series with a total of 26 cases and case reports of the remaining 36 cases. Both Neville et al. 3 and Rojas et al. 2 derived their case series from population-based cancer databases. The median age for presentation was 14 years (range, 10 days to 18 years; interquartile range [IQR]: 11 to 17 years). Tables 1 and 2 provide summary data of the included studies in further detail and Table 3 summarizes the presenting complaints. Full study data are summarized in Supplement B Table 1 .
BAC/AIS. Twenty-one cases involving AIS, formerly referred to as BAC, were included. This included 4 cases in a case series and 14 case reports of 17 patients. 2 The median age in this group was 11 years old (range, 3 days to 18 years; IQR: 6 to 15 years). Tables 2 and 4 provide a summary of the included studies. Full study data are summarized in Supplement B Table 2 .
Adenocarcinoma
Presentation and Diagnosis. Presenting symptoms for adenocarcinoma cases are described in Table 3 . The most common symptoms at diagnosis were respiratory in nature, predominately cough, chest pain, dyspnea, and hemoptysis. In seven cases, diagnosis was reached after a failed trial of antibiotics for presumed respiratory tract infection. Only one patient was reported to be a smoker (17-year-old female, one-half pack-year history). 34 As shown in Tables 1 and 2 , a significant proportion of patients in case series and reports had metastatic disease at diagnosis. The majority of patients had imaging with chest radiograph and computerized tomography, with positron-emission tomography used for staging in seven cases. Histology, when subtyped according to the classification in use at the time of the report, described seven mucinous, six poorly differentiated, four fetal adenocarcinomas, one papillary, and one mixed mucinous and papillary adenocarcinoma. Data on immunohistochemistry or somatic mutation analysis were provided for 20 cases, identifying 3 cases as ALK-positive using immunohistochemistry and fluorescence in situ hybridization confirmation, and 9 cases of EGFR-negative adenocarcinoma, with a variety of other cellular proteins (none targetable by specific therapies), as listed in Table 2 . No cases with an activating EGFR mutation were identified in this systematic review. Tables 1 and 2 , the majority of patients received some form of treatment. Six patients did not receive any treatment for their primary disease even though only one of these patients presented after 1975. 38 In patients undergoing local surgical management, lobectomy was the most frequent procedure. Systemic treatment, either as chemotherapy or molecularly targeted agents, was used in 27 cases (43.5%) with a variety of regimens and often in combination with other treatment modalities. Where described, Outcomes. The overall mortality rate for the case reports was 50% at final follow-up. When considering cases reported after 2000 (excluding predominately autopsy data), the mortality rate was 46%. Both case series described a 26% 5-year survival rate, with the case series from Neville et al. 3 reporting a median survival of 14 months. The median follow-up for all case reports was 1.25 years (IQR: 0.6 to 4 years). For the total study group, 11 of 36 cases (31%) were disease-free, and for cases published after 2000, 13 of 24 cases (54%) remained disease free. The median survival of those in all case reports who died from disease was 8 months, possibly reflecting the fact that several studies included in this review describe post-autopsy diagnosis of primary lung adenocarcinoma after a brief illness. The more recent cases (published after 2000) had a median survival of 13 months from diagnosis to death. Three patients were treated with the ALK-inhibitor crizotinib. 28, 32 One died from disease (ALK-rearrangement) and two were alive with disease at reporting (one ALKrearrangement and one ROS-translocation-positive). These two were the only patients treated with systemic therapy alone who survived to final reported follow-up. For cases published after 2000, stage-based survival was as follows: For stage I, all four patients survived to final follow-up (median follow-up 2 years); for stage II, all three survived (median follow-up 2 years); for Stage III, two patients died of disease and one was alive at final follow-up with median survival 2 months. In comparison, six patients (46%) with stage IV adenocarcinoma died from disease and seven were alive (54%) with median survival of 11 months.
Treatment. As shown in
BAC/AIS
Presentation and Diagnosis. Presenting symptoms for AIS, previously described as BAC, are similar to adenocarcinoma, namely, nonspecific symptoms such as cough, chest pain, and recurrent infections. Four cases were found incidentally on imaging. One case was diagnosed antenatally. 51 Only two studies had further immunohistochemistry performed. 51, 52 Ten cases (45%) were identified within congenital pulmonary adenomatoid malformations. Six cases were metastatic at diagnosis, with the contralateral lung being the most common site of metastasis. When comparing histopathology at time of publication with the current WHO classification, eight cases change from being AIS to a diagnosis of adenocarcinoma proper. 53 The three patients who died at follow-up had their cancer redefined, as did those with metastatic disease as this is contrary to the definition of AIS. Tables 1 and 4 , 16 of 21 (76%) AIS cases were managed surgically. Two cases were managed with adjuvant chemotherapy and no cases received radiotherapy.
Management. As shown in
Outcomes. The case series from Rojas et al. 2 of four patients had a 5-year survival of 50%. In the case series, three patients died, eight were disease free at follow-up and six patients were lost to follow-up or outcomes were not reported. One patient treated with chemotherapy died of progressive disease, wherein AIS transformed into metastatic adenocarcinoma over 15 years of followup. 54 For cases published after 2000, stage-based survival was as follows: for stage 0, there was one death and three survived to final follow-up with median survival 3 years; and for stage IV, one patient was alive at final follow-up (median reported survival 15 years). Two cases did not report outcome data.
Discussion
There is a paucity of data regarding management and outcomes of pediatric adenocarcinoma of the lung. Our systematic review identified 62 cases of adenocarcinoma and 21 cases of AIS from the English literature, 53 of which are from case reports. The median age of presentation with adenocarcinoma was 14 years, and that for AIS was 11 years old, although prenatal diagnoses were made in three cases (including one AIS), indicating that this rare condition affects children of any age. There is a female preponderance, which differs from data in adults younger than 40 years of age. 8 Only one patient was reported to be a regular smoker, and one patient had tuberculosis which was treated during therapy. 37 The majority of case reports were of suitable quality for the purposes of the review, although some lacked examination findings or adequate description of imaging. Three cases of AIS had follow-up duration of 3 months or less and six did not have any outcome reported. Multiple presenting symptoms noted in most reports. These are data from the case report references.
Primary lung adenocarcinoma has a poor prognosis in children, with Neville et al. 3 and Rojas et al. 2 reporting 26% 5-year survival rate in their series. Case studies reported a mortality of approximately 51%. When we focus on cases after 1975 (i.e., exclude older studies which predominately presented autopsy findings), the mortality is 52%. For all cases (from 1888 to 2018), the majority of deaths were lung cancer-specific. Considering the 24 most recent case reports (from 2000 to 2018), 13 (54%) were alive at final follow-up, with 9 (38%) disease free. The mortality rate is therefore similar to all historic cases, despite changes in diagnostics, treatment protocols, and newer systemic treatment options. In comparison, AIS had a mortality rate of 24%. The reported deaths were from metastatic or progressive disease, which would necessitate reclassification of these tumors to adenocarcinoma based on their invasive nature.
As indicated by multiple authors, presenting features of disease were nonspecific and as such often lead to a delayed diagnosis. While respiratory tract infections are far more prevalent, there is a need for further investigation where multiple trials of antibiotics fail to improve symptoms or chest imaging remains persistently abnormal. 5, 12 Delayed diagnosis may have a role in the higher prevalence of metastatic disease at presentation.
3,11 Our review shows that metastatic disease was present at presentation in close to half of all pediatric patients. Whether this reflects unique tumor biology is unclear and not supported by general consensus, although the ability of the child to tolerate and compensate for a pulmonary mass may mask symptoms for some time. 14 The single institution retrospective series by Yu et al. 4 provides a diagnostic algorithm for investigation of pediatric and adolescent primary lung tumors. Further imaging with positron-emission tomography will also enable clarification of metabolic activity for staging and assessing treatment response. Given the preponderance of AIS associated with congenital pulmonary adenomatoid malformations, any cystic lung disease should be thoroughly investigated to rule out neoplasia.
Biopsied tissue found to be adenocarcinoma should be tested for a variety of oncogene driver mutations, including EGFR, KRAS, BRAF, ROS-1, and ALK. Drugs are available to potentially target these specific mutations; in adult lung cancer patients with some of these mutations, outcomes are significantly improved when treated with targeted agents when compared with chemotherapy. These markers also have prognostic implications. 18 EGFR mutations are more common in Asian, female, and older (nonpediatric) patients, and no patients in our review were EGFR-mutation-positive. 33 When we consider the 24 cases reported after 2007 (the year the association between ALK rearrangement and NSCLC was first described), we found two cases were ALK-positive and one was ROS-positive. 65 These mutations are now targetable -drugs including crizotinib, ceritinib, and a Because of changes in nomenclature, we refer to adenocarcinoma in situ where bronchioloalveolar carcinoma had been described. This table was based upon the histopathologic diagnosis made at the time of case publication using their contemporary classification system, though eight of these cases are now classified as adenocarcinoma based upon the latest WHO classification. alectinib have shown significant activity in the adult ALK-positive lung adenocarcinoma populations in advanced-stage disease. 19, 32, [66] [67] [68] From our review, the first reported case where crizotinib was used in pediatric lung adenocarcinoma was by Kim et al. 32 showing therapeutic benefit. Alectinib, a second-generation ALKinhibitor, has been shown to be superior to crizotinib in two randomized phase 3 trials in adult patients with ALK-rearranged lung adenocarcinoma, although its safety and efficacy in pediatric and adolescent lung cancer is yet to be established. 19, 66 Once diagnosis and disease stage are defined, the next major issue is the optimal management of children with lung cancer. No evidence-based guidelines exist, and protocols are extrapolated from adult data. This reflects the belief that tumor biology is the same across age groups. Only one case before 1975 received treatment with radiotherapy. 46 After 1976, all cases except one received some form of treatment. 38 For the 26 cases post-1975 receiving any treatment, 14 of 27 (54%) had some surgical management, whether as sole management or combination therapy, including 12 of 24 (50%) cases after 2000. This is greater than proportions reported in other studies of adults younger than 40 years of age, but is in keeping with general trends that younger people with adenocarcinoma are more likely to have surgery, even where disease is metastatic, possibly due to better performance status in younger people, clinician bias, and clinician interpretation of guidelines for resection of primary disease in stage IV NSCLC. 6, 7, 20 In case series from Neville et al. 3 and Rojas et al. 2 , 10 patients had surgery for the adenocarcinoma. The population study from Neville et al. 3 showed surgery to be an independent positive prognostic factor for survival and should therefore be considered an option where feasible. In comparison, 76% of AIS was managed with surgery. The recommendation for surgery needs to be based upon patient disease stage and performance status, with guidelines recommending it only where limited metastatic disease is present. According to the NCCN guidelines, disseminated metastatic disease should be managed with systemic chemotherapy alone.
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Systemic therapy was administered to 27 of 62 patients with adenocarcinoma and two cases of AIS. A variety of regimens were used following established adult protocols. There are no pediatric-specific protocols for lung cancer chemotherapy and, given its rarity, it is unlikely that evidence-based guidelines will ever be generated in the pediatric population. Some patients received several cycles of different agents, although no patient managed with systemic treatment alone survived more than 19 months. The exceptions are two of the three patients managed with crizotinib who were alive with disease up to 18 months post-diagnosis. 28, 32 This is the first systematic review of the pediatric lung adenocarcinoma approach to management. Our systematic search strategy has identified, to the best of our knowledge, all English literature on the subject, dating from 1888 to 2018. While we have included all historic cases for completeness and to highlight the rarity of pediatric lung adenocarcinoma, it is difficult to glean useful information from the older cases; thus, we provide subset analyses from studies published after 2000. In comparison to the two case series reviewed here, we have added further cases and provided additional data on gene mutation testing which is of use given the ability to target mutations such as ALK and EGFR. We analyzed AIS (formerly BAC) separately because of recent changes in WHO criteria which mean some are now classified as mucinous adenocarcinoma whereas others remained AIS. 53 As such, a synthesis of prognostic and treatment recommendations from these cases may be problematic. We have provided stage-based survival data for cases reported after 2000. However, interpretation of these data is limited as patients in each stage had different treatments and follow-up duration. Several stages (such as stage III adenocarcinoma) have too few cases for adequate median survival data.
This systematic review is limited by small patient numbers and the low-grade (level 4) evidence generated from limited database-derived case series and case reports. This means formulating age-specific evidencebased recommendations is difficult. Discussion of these patients in an adult lung cancer multidisciplinary meeting should be a priority, as treatment guidelines and recommendations still closely mirror adult lung cancer management guidelines. Collaboration between adult and pediatric pathologists and oncologists is important to facilitate optimal diagnosis and application of adult therapeutic evidence where it exists in the setting of rare pediatric tumors which are common in adults (as with lung adenocarcinoma). Improving access to clinical trials, where appropriate, will ensure equitable access to standard-of-care adult medications in a pediatric setting and a stronger evidence base for managing pediatric lung cancer. Pediatric lung adenocarcinomas should undergo oncogene mutation and molecular screening to identify potentially targetable mutations, which may offer the option of treatment with specific targeted agents. To improve our understanding of the biology, pathology, and management of pediatric lung adenocarcinoma, we propose the establishment of a prospective international registry of new pediatric and adolescent lung adenocarcinoma cases to assist in the development of management guidelines in this specific age group, which could also potentially accommodate strategies to address the unique medical and psychosocial needs of the young patient and their family.
